IA
TNYA icon

IFP Advisors’s Tenaya Therapeutics TNYA Stock Holding History

IFP Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.42K Hold
5,978
– – ﹤0.01% 3862
2026
Q1 		$4.14K Buy
5,978
+5,962
+37,263% +$4.4K ﹤0.01% 3631
2025
Q4 		$11 Sell
16
-490
-97% -$666 ﹤0.01% 4836
2025
Q3 		$820 Sell
506
-803
-61% -$809 ﹤0.01% 4020
2025
Q2 		$800 Buy
+1,309
New +$666 ﹤0.01% 4293

Other funds holding TNYA

MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return
AWM
Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
VWM
Vermillion Wealth Management Rosemount, Minnesota $427M AUM 12.63% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

IFP Advisors's TNYA Position: Q2 2026 in Review

IFP Advisors held its Tenaya Therapeutics (TNYA) position steady in Q2 2026 at 5,978 shares worth $4.42K. The position accounts for ﹤0.01% of the portfolio, ranked #3862.

IFP Advisors first reported a position in TNYA in Q2 2025 and has held it in 5 quarters since. 9 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • IFP Advisors held 5,978 shares of Tenaya Therapeutics worth $4.42K as of Q2 2026.
  • IFP Advisors left its Tenaya Therapeutics share count unchanged in Q2 2026.
  • Tenaya Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3862 holding.
  • IFP Advisors first reported a position in Tenaya Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 9 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.